Vupanorsen + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
Trial Timeline
Sep 28, 2020 → Dec 6, 2021
NCT ID
NCT04516291About Vupanorsen + Placebo
Vupanorsen + Placebo is a phase 2 stage product being developed by Pfizer for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT04516291. Target conditions include Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04516291 | Phase 2 | Completed |
| NCT04459767 | Phase 1 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 33 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 85 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 33 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 52 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 30 |